US FDA launches ultra-rare diseases framework
The draft guidance specifically discusses genome editing and RNA-based therapies
Read More
Section: Healthcare
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Read More
Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic
The reduction in price to $675 will take effect at the beginning of next year
Read More
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Read More
Pandemic readiness is now a financial risk test – and the UK must treat it that way
COVID-19 showed how quickly a health emergency becomes a fiscal event: disrupting supply chains, reshaping capital allocation and exposing governance weaknesses
Read More